China World Technology Medical Equipment Service Group
Win-win together!
Brand Name: | Mindray |
Minimum Order Quantity: | 1pcs |
---|---|
Packaging Details: | Carton |
Delivery Time: | 3-5 working days |
Payment Terms: | T/T(wire transfer), Western Union, Paypal |
Product Name: | Mindray Multi-Parameter Patient Monitor Picco Module Available Used | Brand: | Mindray |
---|---|---|---|
MOQ: | 1 Piece | Condition: | Used |
Delivery Time: | Around 5 Working Days | Delivery Method: | DHL,UPS ,Fedex ,etc |
Application: | Hospital ,Clinic ,etc | Type: | Module |
Description: | PICCO Module | ||
Highlight: | Multi Parameter Patient Monitor Picco Module,Mindray Patient Monitor Picco Module |
Mindray Multi-Parameter Patient Monitor Picco Module Available Used
The Mindray PICCO module is designed for continuous monitoring of cardiac output using a Beneview patient monitor with central venous catheter and axillary or femoral artery catheter. PiCCO Technology is a unique combination of transpulmonary thermodynamic measurement and pulse contour analysis for advanced hemodynamic and volumetric management.
Continuous Cardiac Output CCO | CCI |
Stroke Volume SV | SVI |
Systemic Vascular Resistance SVR | SVRI |
Cardiac Power Output CPO | CPI |
Stroke Volume Variation | SVV |
Pulse Pressure Variation |
PPV
|
Left Ventricular Contractility |
dPmx
|
Heart Rate | HR |
Mean Arterial Blood Pressure | pArt-M |
Systolic Arterial Blood Pressure |
pArt-S
|
Diastolic Arterial Blood Pressure |
pArt-D
|
Cardiac Output C.O. | C.I. |
Global End-Diastolic Volume GEDV | GEDI |
Extralvascular Lung Water EVLW | ELWI |
Global Ejection Fraction |
GEF
|
Pulmonary Vascular Permeability Index |
PVPI
|
Cardiac Function Index | CFI |
Intrathoracic Blood Volume ITBV | ITBI |
PiCCO technology was introduced by Munich-based Pulsion Medical Systems in 1997 and has been continuously improved since then. Pulsion has more than 20 years of experienceIn Hemodynamic monitoring experience. PiCCO technology is now the established standard for advanced hemodynamic monitoring, validated by modular integration in monitors from world leaders in the patient monitoring market such as PHiliphhilip / Dixtal, Dräger, GE and Mindray. During the past 15 years, approximately 1,000 publications worldwide have the following clinical applicability and accuracy.
PiCCO technology is used more than 140,000 times a year in more than 60 countries.
The PiCCO technology is based on two PHiliphhilipysical principles.
Transpulmonary thermal dilution and pulse contour analysis. two
The principle allows the calculation of hemodynamic parameters,
They have been clinically proven and have been established for over 20 years.
Arterial pulsation contour analysis
Pulse contour analysis provides continuous information and transpulmonary thermal dilution provides static measurements. Transpulmonary thermal dilution
For the transpulmonary thermal dilution measurements of the pulse contour parameters, a defined bolus (for example, 15 ml of cold saline) is injected through a central venous catheter.
The left heart is usually detected by a PiCCO catheter placed in the femoral artery. This procedure should be repeated approximately 3 times within 10 minutes to calibrate the unit with exact averages and calculate the thermal dilution parameters. These thermal dilution parameters (that is, updated only when the thermal dilution procedure is performed). It will be reviewed when there is a significant change
About the patient's condition and treatment. We recommend that you calibrate your system at least three times a day.
Indications and benefits
Signs of PiCCO
PiCCO technology is suitable for patients with unstable hemodynamics, uncertain volume conditions, and treatment conflicts. These situations are generally in the following locations:
• Septic shock
• Cardiogenic shock
• Traumatic shock
• ARDS
• Severe burns
• Pancreatitis
• High-risk operations
Medical benefits
Surveillance alone cannot reduce patient mortality or morbidity. However, it does provide valuable information that can be used to develop treatment plans so that targeted therapies can be applied to patients as soon as possible. The success of Early Targeted Therapy (EGDT) is documented in well-documented studies
The following advantages:
• Reduce ventilation time
• Reduce the length of stay in the intensive care unit
• Reduce complications
• Reduce recovery time
Contact Person: Kiara
Tel: 8619854815217